Rockin Robin SongFlying The Web For News.
RobinPost Logo Amazon Prime Deals





Globe NewsWire News Distribution Service


Geneva, Switzerland and Westport, CT, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Launched today, the Alliance for Advancing Bioelectronic Medicine (AABM) is an independent network of professionals united to advance bioelectronic medicine – one of the most innovative and exciting fields in healthcare. The alliance aims to align bioelectronic medicine leaders on shared goals, facilitate cross-sector collaboration, mobilize key external audiences, and build awareness of the field overall.

“Bioelectronic medicine represents a tremendous opportunity to improve patients’ lives and change our world. However, achieving this will require much greater collaboration and awareness from a much larger and more diverse group of stakeholders,” said Kenneth L. Londoner, Founder, CEO, and Chairman of BioSig Technologies, a medical technology company that has supported creation of AABM. “We believe that the Alliance for Advancing Bioelectronic Medicine will play a much-needed role by aligning and amplifying voices in the field, winning over new allies, and driving progress that, ultimately, benefits everyone.”

The alliance brings together leaders in bioelectronic medicine: a rapidly growing field of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a range of diseases. Its members are committed to realizing the potential of bioelectronic medicine to transform diagnosis and care for millions of people, particularly in areas of unmet need such as Parkinson’s disease, major depressive disorder, treatment-resistant epilepsy, heart arrhythmia, and chronic pain.

“The Alliance for Advancing Bioelectronic Medicine will support greater collaboration among experts across different sectors, disease areas, disciplines, and specialties,” said Samuel Asirvatham, M.D. a founding member of AABM and Vice Chair, Innovation and Medical Director, Electrophysiology Laboratory, Cardiovascular Diseases at the Mayo Clinic. “The collaboration hopes to pave the way to novel diagnostics and treatment options for patients.”

 The alliance grew out of an invitation-only roundtable in the spring of 2019, at which a distinguished group of researchers, entrepreneurs, and healthcare experts agreed on the need for an ongoing dialogue to advance a shared vision for bioelectronic medicine and a catalyst to unite the field. Since that gathering, members have developed a consensus on a shared definition, a unified narrative, and a set of tailored messages for the many groups that stand to benefit from bioelectronic medicine.

“We’ve seen impressive scientific and medical progress in bioelectronic medicine in recent years,” said Dr. Hein Heidbuchel, Professor and Chair of Cardiology, Antwerp University and President of the European Heart Rhythm Association. “But what has been missing is a compelling story that builds understanding and support for this field across a wide range of relevant audiences.”

The Alliance for Advancing Bioelectronic Medicine aims to play a unique convening role, mobilizing patients, physicians, and other stakeholders to advocate for the field, and increasing awareness among audiences that are important for the field’s growth, including policymakers, investors, media, and the general public. Its steering committee includes experts with experience at Battelle, European Heart Rhythm Association, The Feinstein Institute, Heart Rhythm Society, Imperial College London, Mayo Clinic, RAND Corporation and Sheba Medical Center. 

The alliance will be coordinated by High Lantern Group, a strategic positioning firm active in global health policy. “We see great potential for bioelectronic medicine to help serve unmet medical needs and achieve healthier societies,” said Mario Ottiglio, Managing Director at High Lantern Group. “We look forward to collaborating with this community to shape a compelling policy agenda that attracts broad support and helps accelerate the growth of this nascent industry.”

For more information, please contact:

Ms. Julie Pierce

Managing Director

High Lantern Group 

Ms. Natasha Drapeau

Executive Vice President

BioSig Technologies, Inc.


info@advancingbioelectronicmedicine.org

+1 203-409-5444, x119  

Meryl Ellingson
High Lantern Group
6263442722
mellingson@highlanterngroup.com


Posted: 2019-11-18 23:41:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



More News From This Category
Press Release: Levi & Korsinsky Announces Investigation of Securities Claims Against Verra Mobility Corporation (VRRM)
Mon, 01 Jun 2026 19:07:42 +0000

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Investors holding Verra Mobility Corporation (NASDAQ: VRRM) shares watched up to 46% of their investment disappear on May 26, 2026, after the Company cut its FY-2026 revenue guidance by $135 million to $145 million following the termination of a major customer contract. Shareholders who lost money on…

Read More ...


Press Release: BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avanos Medical, Inc. (NYSE – AVNS), Global Business Travel Group, Inc. (NYSE – GBTG), LiveRamp Holdings, Inc. (NYSE – RAMP), Equity Residential (NYSE –
Mon, 01 Jun 2026 16:07:41 +0000

BALA CYNWYD, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Read More ...


Press Release: Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
Mon, 01 Jun 2026 13:07:41 +0000

DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.

Read More ...


Press Release: EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask
Mon, 01 Jun 2026 10:07:38 +0000

SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced it is expanding the Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask (“Regenixé Mask”),…

Read More ...


Press Release: Ekstraordinære indfrielser (CK 93)
Mon, 01 Jun 2026 07:07:39 +0000

I medfør af kapitalmarkedsloven § 24, oplyser DLR Kredit hermed om ekstraordinære indfrielser pr. fredag den 29 maj 2026. Oplysningerne fremgår af vedhæftede fil. Denne meddelelse er offentliggjort med henblik på opfyldelse af transparensdirektivets krav om offentliggørelse. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen.Spørgsmål kan rettes til: Head of Rating & IR Jakob…

Read More ...


Related Bing News Results





















Blow Us A Whistle


Related Product Search/Búsqueda de productos relacionados

Amazon Logo

Visit Our New Print-On-Demand Stores On Printify and Zazzle
Printify Zazzle